PTGX — Protagonist Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $3.29bn
- $2.71bn
- $434.43m
- 73
- 33
- 83
- 68
Annual cashflow statement for Protagonist Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -66.2 | -126 | -127 | -79 | 275 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 8.68 | 18.2 | 23.7 | 24.9 | 28.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -19 | -3.31 | -7.77 | -19.5 | -123 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -72.5 | -108 | -108 | -70.2 | 184 |
| Capital Expenditures | -0.471 | -1.1 | -0.795 | -0.609 | -1.35 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -90.5 | -14.8 | 92.3 | -38.6 | -298 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -91 | -15.9 | 91.5 | -39.3 | -299 |
| Financing Cash Flow Items | -0.014 | -0.189 | -0.163 | -0.769 | -0.6 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 248 | 130 | 18.8 | 170 | 25.9 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 84.4 | 6.07 | 2.08 | 61 | -89.5 |